---
search:
  boost: 3
---

# Sedative-Hypnotics, Non-Barbiturate

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Trees

- [CNS - Sedative-Hypnotics, Non-Barbiturate - Controlled Medications – Belsomra, Dayvigo, Eszopiclone, Intermezzo, Quviviq, Temazepam 7.5, Temazepam 22mg, Zolpidem ER, Zolpidem SL](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMlpFWDc3MDExSjg2S1hUOUY4TU5LNjRHNiQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Sedative-Hypnotics, Non-Barbiturate - Non-Controlled Medications – Doxepin 3 and 6mg, Ramelteon](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURTBUS0tFOUZGUlpYTkpJMVNGS09RR0YyTSQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                         | Generic Name                          | Quantity | Time (Days) |
| :-------------------------------- | :------------------------------------ | :------: | :---------: |
| Estazolam <sup>QL</sup>           | Estazolam Tab (all strengths)         |    34    |     34      |
| Temazepam 15, 30 MG <sup>QL</sup> | Temazepam Cap 15 MG & 30 MG           |    34    |     34      |
| Zaleplon <sup>QL</sup>            | Zaleplon Cap (all strengths)          |    34    |     34      |
| Zolpidem <sup>QL</sup>            | Zolpidem Tartrate Tab (all strengths) |    34    |     34      |

### Non-Preferred

| Non-Preferred                      | Generic Name                    |         Quantity          |        Time (Days)        |
| :--------------------------------- | :------------------------------ | :-----------------------: | :-----------------------: |
| Belsomra                           |                                 |                           |                           |
| Dayvigo                            |                                 |                           |                           |
| Doxepin 3, 6 MG                    |                                 |                           |                           |
| Eszopiclone <sup>QL</sup>          | Eszopiclone Tab (all strengths) | Determined pursuant to PA | Determined pursuant to PA |
| Intermezzo                         |                                 |                           |                           |
| Quviviq                            |                                 |                           |                           |
| Ramelteon                          |                                 |                           |                           |
| Temazepam 7.5, 22 MG <sup>QL</sup> | Temazepam Cap 7.5 MG & 22.5 MG  | Determined pursuant to PA | Determined pursuant to PA |
| Zolpidem ER, SL                    |                                 |                           |                           |

## Authorizations

**Length of Authorizations**: 180 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^10 days^^ with at least ^^two preferred^^ drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Additional Information

- Non-controlled medications may be authorized if the prescriber indicates the patient has a history of addiction
- The P&T Committee does not recommend the use of flurazepam (Dalmane) or triazolam (Halcion)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=47){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=18){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
